Conditional

BioAtla to Participate in the Citizens JMP Life Sciences Conference

Retrieved on: 
Mercredi, mai 8, 2024
Citizenship, Therapy, Conference, SAN, CAB, Conditional

SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will participate in a fireside chat and one-on-one investor meetings at the Citizens JMP Life Sciences Conference, to be held in New York, NY May 13-14, 2024.

Key Points: 
  • SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will participate in a fireside chat and one-on-one investor meetings at the Citizens JMP Life Sciences Conference, to be held in New York, NY May 13-14, 2024.

BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024

Retrieved on: 
Mardi, mai 7, 2024
News, Press release, Therapy, Webcast, SAN, CAB, Conditional

SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Tuesday, May 14, 2024 at 4:30 p.m.

Key Points: 
  • SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Tuesday, May 14, 2024 at 4:30 p.m.
  • ET to discuss its financial results for the first quarter ended March 31, 2024 and provide business highlights.
  • The press release with the financial results will be accessible prior to the conference call through “ News Releases ” in the News & Events section of the company’s website.
  • A replay of the call will also be available through “ Events & Presentations ” in the Investors section of the company’s website.

BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors

Retrieved on: 
Lundi, mai 6, 2024
FDA, Immortalised cell line, CAB, Food, Brentuximab vedotin, IND, Therapy, ADC, Therapeutic index, Conditional, Serum, Toxicity, Nextgen, SAN, Pharmaceutical industry

ADC is a promising treatment modality with broad applicability across multiple tumor indications.

Key Points: 
  • ADC is a promising treatment modality with broad applicability across multiple tumor indications.
  • The CAB technology is designed to eliminate or reduce both on-target, off-tumor and off-target, off-tumor toxicities.
  • At the AACR Annual Meeting in April 2024, data showed differentiated anti-Nectin-4-ADC via in vitro and in vivo characterization of its novel next-generation carbohydrate linker system.
  • The NextGen linker system helped eliminate off-target, off-tumor toxicity with substantially improved serum stability and increased hydophilicity thereby improving potency.

BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Retrieved on: 
Mercredi, avril 24, 2024
ASCO, CAB, Therapy, Society, SAN, Nivolumab, Conditional, Pharmaceutical industry

SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting to be held virtually and at the McCormick Place Convention Center in Chicago, Illinois from May 31–June 4, 2024.

Key Points: 
  • SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting to be held virtually and at the McCormick Place Convention Center in Chicago, Illinois from May 31–June 4, 2024.
  • Phase 1 study of BA3071, an anti-CTLA-4 conditionally active biologic, in combination with nivolumab in advanced solid tumors

Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

Retrieved on: 
Mardi, avril 23, 2024
Ulcerative colitis, Cancer, Inflammation, Poster, Colitis, Journal, Disease, IBD, GI, AAI, Treatment, Conditional, Therapy, Autoimmunity, UC, Pharmaceutical industry

WATERTOWN, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL) today announced a poster presenting preclinical data characterizing conditionally-activated IL-10 INDUKINE molecules for the treatment of colitis in animal models, a novel approach leveraging its PREDATOR™ protein engineering platform, at IMMUNOLOGYTM 2024, the annual meeting of the American Association of Immunologists (AAI) taking place May 3-7 in Chicago, Illinois.

Key Points: 
  • Prolonged inflammation results in damage to the GI tract.
  • While the exact cause of IBD is unknown, autoimmune and immune-mediated factors have been shown to contribute to the severity of the disease.
  • Results highlighting Werewolf’s findings are summarized in a poster titled, “Development of Conditionally Active IL-10 INDUKINETM Molecules for the Treatment of Inflammatory Bowel Disease” (Board #B906).
  • The poster can be viewed in person on Monday, May 6, 2024, on board number B906, with Werewolf delegates present from 2:15-3:30pm to answer questions.

SmartRecruiters Unveils Feature Rich April 2024 Release

Retrieved on: 
Jeudi, avril 25, 2024
Interview, UI, Conditional, Data analysis, Communication, Collection, Taxonomy, Occupation, Acquisition, Data management, Fernando Visier Segovia, EOC, SAN

SAN FRANCISCO, April 25, 2024 /PRNewswire/ -- SmartRecruiters , a leader in enterprise talent acquisition software, today announced its latest product release, packed with innovative features designed to streamline the recruitment process and empower hiring teams.

Key Points: 
  • SAN FRANCISCO, April 25, 2024 /PRNewswire/ -- SmartRecruiters , a leader in enterprise talent acquisition software, today announced its latest product release, packed with innovative features designed to streamline the recruitment process and empower hiring teams.
  • This April, users can explore new functionalities within the SmartRecruiters' platform, including advanced AI capabilities, improved integration options, and significant user interface enhancements.
  • This integration is a step towards more advanced workflow capabilities, ensuring efficient communication and task management within recruitment teams.
  • For more information on SmartRecruiters and its latest product release, visit the What's New page .

Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency

Retrieved on: 
Lundi, avril 8, 2024
Patient, Cerebrovascular disease, Stroke, Accelerated approval (FDA), European Medicines Agency, Doctor of Philosophy, Osteomalacia, PROMIS, Therapy, Conditional, Natural history, CTX, Pros, ADAS, Risk, DSM-IV codes, Cohort, Aes, Alkaline phosphatase, Rickets, EMA, PXE, Safety, Epilepsy, Clinical trial, Food, Hospital, Disability, BSAP, Cardiovascular disease, Disease, PD, Paresis, Consultant, Hypophosphatemia, Fatigue, Survivor, Sclera, FDA, Observational study, Pyrophosphate, Choroid, Incidence, Retina, Biomarker, Life, Event, Medical imaging

BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced positive topline safety, pharmacokinetic (PK), pharmacodynamic (PD) and exploratory efficacy data from the Company’s ongoing Phase 1/2 clinical trials of INZ-701 in adults with ABCC6 Deficiency (PXE, pseudoxanthoma elasticum) and ENPP1 Deficiency.

Key Points: 
  • “We are excited by the excellent safety and preliminary efficacy profile of INZ-701 in adults with ABCC6 Deficiency,” said Douglas A. Treco, Ph.D., CEO of Inozyme Pharma.
  • The patients were assigned to three dose cohorts of INZ-701: 0.2 mg/kg (n=3), 0.6 mg/kg (n=3), and 1.8 mg/kg (n=4).
  • For trial design details, please see the section entitled “INZ-701 in ABCC6 Deficiency Phase 1/2 Clinical Trial Design” below.
  • For trial design details, please see the section entitled “INZ-701 in ENPP1 Deficiency Phase 1/2 Clinical Trial Design” below.

BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress

Retrieved on: 
Mardi, mars 26, 2024
Research, AXL, Head, Congress, NSCLC, SAN, Patient, Webcast, Observation, G&A, Peripheral neuropathy, CAB, Melanoma, D&O, Sarcoma, CD3, AACR, DLT, Conditional, ESMO, SITC, Therapy, ADC, Annual general meeting, SCCHN, Pharmaceutical industry

General and administrative (G&A) expenses were $5.9 million for the quarter ended December 31, 2023 compared to $6.7 million for the same quarter in 2022.

Key Points: 
  • General and administrative (G&A) expenses were $5.9 million for the quarter ended December 31, 2023 compared to $6.7 million for the same quarter in 2022.
  • Net loss for the quarter ended December 31, 2023 was $26.9 million compared to a net loss of $27.6 million for the same quarter in 2022.
  • Cash used for the quarter ended December 31, 2023 was $29.8 million.
  • Cash and cash equivalents as of December 31, 2023 were $111.5 million, compared to $215.5 million as of December 31, 2022.

Mattr Corp. Announces Pricing of Upsized Senior Unsecured Notes Offering

Retrieved on: 
Mardi, mars 19, 2024
TD Securities, Offering, Sale, Regulation, TSX, Conditional

TORONTO, March 19, 2024 (GLOBE NEWSWIRE) -- Mattr Corp. (“Mattr” or the “Company”) (TSX: MATR) announced today that it has entered into an underwriting agreement to sell, pursuant to a private placement offering (the “Offering”), C$175 million aggregate principal amount of 7.25% senior unsecured notes due 2031 (the “Notes”), which aggregate principal amount of notes was upsized from the initial deal size of C$150 million.

Key Points: 
  • TORONTO, March 19, 2024 (GLOBE NEWSWIRE) -- Mattr Corp. (“Mattr” or the “Company”) (TSX: MATR) announced today that it has entered into an underwriting agreement to sell, pursuant to a private placement offering (the “Offering”), C$175 million aggregate principal amount of 7.25% senior unsecured notes due 2031 (the “Notes”), which aggregate principal amount of notes was upsized from the initial deal size of C$150 million.
  • The Notes will be issued at a price of C$1,000 per C$1,000 principal amount of Notes.
  • “Over the last three years Mattr has completed a fundamental business transformation while delivering substantial growth and significantly strengthening our balance sheet.
  • Subject to customary closing conditions, the Offering is expected to close on or about April 2, 2024.

BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024

Retrieved on: 
Mardi, mars 19, 2024
Webcast, Therapy, SAN, News, Conditional, Press release, CAB

SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Tuesday, March 26, 2024 at 4:30 p.m.

Key Points: 
  • SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Tuesday, March 26, 2024 at 4:30 p.m.
  • ET to discuss its financial results for the fourth quarter and full-year ended December 31, 2023 and provide business highlights.
  • The press release with the financial results will be accessible prior to the conference call through “ News Releases ” in the News & Events section of the company’s website.
  • A replay of the call will also be available through “ Events & Presentations ” in the Investors section of the company’s website.